Article
A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
Lung cancer (Amsterdam, Netherlands) - 1 Jun 2017
Moran Teresa, Palmero Ramón, Provencio Mariano, Insa Amelia, Majem Margarita, Reguart Noemí, Bosch-Barrera Joaquim, Isla Dolores, Costa Enric Carcereny, Lee Chooi, Puig Marta, Kraemer Sandrine, Schnell David, Rosell Rafael
Abstract excerpt
OBJECTIVES: Dysregulation of the downstream PI3K/AKT/mTOR signaling pathway is a proposed mechanism of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). We investigated safety and antitumor activity of afatinib plus sirolimus as a potential combination to reverse acquired resistance to EGFR-TKIs in a phase IB trial in patients with EGFR mutation-positive non-small-cell lung...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.